Table 2 Management of serum phosphate levels during open-label run-in phase
| Â | Serum Phosphate (mmol/L) | Action |
|---|---|---|
Week 2 | <0.8 | Reduce dose to 800 mg tds and continue to week 4 |
| Â | >0.8 | Continue to week 4 |
Week 4 | <0.8 | Reduce dose to 800 mg tds and continue to week 6 If already on 800 mg tds withdraw from study after week 4 visit |
| Â | >0.8 | Randomise |
Week 6 | <0.8 | Final measurements and withdraw from study |
| Â | >0.8 | Randomise |